Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20148884 | 0.88 | HIF1A (0.38) | HIF1AEPAS1CNR2PTPN1HSD17B10 | |
| SCHEMBL20161157 | 0.85 | CACNA1B (0.32) | — | |
| SCHEMBL20161158 | 0.84 | HIF1A (0.41) | HIF1AEPAS1PTPN1GABRA1GABRA5 | |
| SCHEMBL20161155 | 0.84 | KCNK13 (0.32) | — | |
| SCHEMBL20161109 | 0.84 | PLA2G7 (0.31) | — | |
| SCHEMBL20161159 | 0.82 | — | — | |
| SCHEMBL20148877 | 0.82 | AR (0.39) | HIF1AEPAS1CNR2PTPN1HSD17B10 | |
| SCHEMBL20141194 | 0.79 | HIF1A (0.37) | HIF1AEPAS1PTPN1GABRA1GABRA5 | |
| SCHEMBL20161156 | 0.78 | CNR2 (0.34) | HIF1AEPAS1CNR2HSD17B10 | |
| SCHEMBL20140383 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538096-B1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-11-30 | — | — | US | disclosed |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20210177846-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | TISENTO THERAPEUTICS INC. | 2021-06-17 | — | — | US | disclosed |
| US-20190343813-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| EP-3538520-A2 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018111795-A2 | USE OF SGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018089328-A1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343813-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | HIF1A 2099/4885EPAS1 706/4885CNR2 487/4885 |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | GUCY1A2, GUCY1B2, PDE2A | HIF1A 2099/4885EPAS1 706/4885CNR2 487/4885 |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | HIF1A 2099/4885EPAS1 706/4885CNR2 487/4885 |
| US-20210177846-A1 | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | CS, COQ8A, GLS | HIF1A 1259/4885EPAS1 938/4885CNR2 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.